Today, Atomo Diagnostics and Owen Mumford Ltd announced a strategic partnership for commercialisation of innovative HIV rapid tests in European markets
Owen Mumford is a major healthcare company and device manufacturer that commercialises pioneering medical products in its own brand to enhance access to diagnostics, encourage adherence to treatment and reduce healthcare costs – “making a world of difference to a world of people”. Producing class-leading medical devices that are used globally, Owen Mumford exports over 85% of its products to more than 60 countries worldwide.
The new Strategic Partnership sees Owen Mumford acquire exclusive rights to Atomo’s range of CE-Marked in vitro HIV rapid diagnostic tests (RDTs) for commercialisation via its established sales and distribution networks under its Simplitude ™ brand. Initially focused on professional use testing in Europe, we are currently exploring options to extend the agreement to cover HIV self-testing.
Atomo’s CEO John Kelly explains what this new partnership means for the company: “We are extremely excited to be working with such a long-established and respected partner as Owen Mumford. This strategic partnership offers significant mutual benefits and, by leveraging Owen Mumford’s established sales network, will support the roll-out of Atomo’s HIV test devices in developed healthcare markets. Our companies have already formed a close working relationship and we are hoping to extend the scope and nature of our collaboration in the months ahead to further support the growth plans of both companies.”
Simplitude ™ HIV will be made available in European markets during 2018.